Philips Healthcare, Therapeutic Monitoring Systems and the Ottawa Hospital Research Institute collaborate to initiate clinical decision support pilot study

July 10, 2012

Andover, Mass., and Ottawa, Ontario --  Royal Philips Electronics (NYSE: PHE, AEX: PHI) and Therapeutic Monitoring Systems (TMS) Inc. today announced a collaboration agreement aimed at the integration of selected Philips cardiopulmonary monitors with clinical decision support software being developed by TMS.  Following integration, a pilot study will be conducted in the intensive care unit (“ICU”) at The Ottawa Hospital under the supervision of Dr. Gwynne Jones, a respirologist and intensivist in the Department of Critical Care Medicine. 

The pilot study will assess several areas, including the performance of technologies and features potentially useful in predicting readiness for discontinuation of mechanical ventilation, providing patient-specific recommendations related to making mechanical ventilation adjustments and exploring the utility of a new measurement device to support ventilator decision-making. Ultimately, the long term goal is to reduce the period of mechanical ventilation, thereby improving patient comfort, preventing related complications such as ventilator-associated pneumonia, and reducing costs.

Said Dr. Adam Seiver, chief of Medical Affairs, Therapeutic Care, for Philips Healthcare: “We are very pleased to be working with TMS and the medical staff and researchers at The Ottawa Hospital on this initial project. As a leader in respiratory monitoring and clinical decision support, Philips regards the integration of advanced clinical decision support software analytics with monitoring as fundamental to our vision of providing actionable point-of-care monitoring to improve both patient care and efficiencies in the ICU.”

Commented Simon Goulet, TMS’ Chief Operating Officer: “The agreement with Philips represents important validation of our belief that vital sign analytics are key to advancing patient monitoring and care in the ICU.  Interest in our clinical software platform by a global leader in critical care medicine is exciting and we look forward to building on this interest during the coming months.  We are also delighted that the initial study will take place at The Ottawa Hospital, a key clinical partner for us.”

“We rely on Philips monitoring equipment every day to guide us in providing the best possible care for our ICU patients, and we are happy to collaborate with Philips and TMS to advance this technology further,” said Dr. Dave Neilipovitz, Chair and Head of the Department of Critical Care Medicine at The Ottawa Hospital and the University of Ottawa, and Clinical Investigator at the Ottawa Hospital Research Institute.

For further information, please contact:

 

Steve KellySimon GouletJennifer Ganton
   
Philips Healthcare
Tel: +1 (425) 487-7479
steve.kelly@philips.com
Therapeutic Monitoring Systems
Tel: +1 (613) 368-4311 x 403
sgoulet@therapeuticmonitoring.com
Ottawa Hospital Research Institute
Tel: +1 (613) 798-5555 x 73325
jganton@ohri.ca 
.

About Royal Philips Electronics

Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a diversified health and well-being company, focused on improving people’s lives through timely innovations. As a world leader in healthcare, lifestyle and lighting, Philips integrates technologies and design into people-centric solutions, based on fundamental customer insights and the brand promise of “sense and simplicity.” Headquartered in the Netherlands, Philips employs approximately 122,000 employees with sales and services in more than 100 countries worldwide. With sales of EUR 22.6 billion in 2011, the company is a market leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as lifestyle products for personal well-being and pleasure with strong leadership positions in male shaving and grooming, portable entertainment and oral healthcare. News from Philips is located at www.philips.com/newscenter.

.

About Therapeutic Monitoring Systems

Based in Ottawa, Ontario, Therapeutic Monitoring Systems is commercializing clinical decision support software applications for use in critical care medicine that offers the potential to materially improve patient care decisions and reduce the cost of patient care.  TMS has licensed technology from the Ottawa Hospital Research Institute.  TMS is a portfolio company of Genesys Capital (www.genesyscapital.com), the MaRS Investment Accelerator Fund (www.marsdd.com/aboutmars/partners/iaf/) & the Queen’s TriColour Venture Fund (www.business.queensu.ca/centres/qcbv/tricolour_venture_fund.php). TMS has also received financial & advisory support from The Health Technology Exchange (www.htx.ca), FedDev Ontario (www.feddevontario.gc.ca), the Ontario Centres of Excellence (www.oce-ontario.org/), the Industrial Research Assistance Program (www.nrc-cnrc.gc.ca/eng/ibp/irap.html), MaRS Discovery District (www.marsdd.com) & the Ottawa Technology Transfer Network (www.ottn.ca/).

.

About The Ottawa Hospital and the Ottawa Hospital Research Institute

The Ottawa Hospital (www.ottawahospital.on.ca) serves 1.2 million people across Eastern Ontario, striving to provide each patient with the world-class care, exceptional service and compassion that we would want for our loved ones. The Ottawa Hospital Research Institute (www.ohri.ca) is the research arm of The Ottawa Hospital and is an affiliated institute of the University of Ottawa, closely associated with the university’s Faculties of Medicine and Health Sciences. The Ottawa Hospital Research Institute includes more than 1,500 scientists, clinical investigators, graduate students, postdoctoral fellows and staff conducting research to improve the understanding, prevention, diagnosis and treatment of human disease.

.